Abe Yasunobu, Choi Ilseung, Ikeda Motohiko, Matsushima Takamitsu, Suehiro Youko, Shiratsuchi Motoaki, Uike Naokuni
Division of Hematology, National Kyushu Cancer Center, National Hospital Organization, and Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University.
Rinsho Ketsueki. 2012 Jun;53(6):632-4.
We measured plasma levels of thrombopoietin (TPO) in several patients with thrombocytopenia. Similar to previous reports, TPO levels in aplastic anemia (N=9) were markedly higher than those in idiopathic thrombocytopenic purpura (N=10): 16.19+/-9.07 fmol/ml and 1.21+/-1.06 fmol/ml, respectively. In patients with secondary failure of platelet recovery (N=7) as well as primary failure after hematopoietic stem cell transplantation, TPO levels were very high, reflecting impaired platelet production due to GVHD, drug treatments, and infection. When using new drugs such as TPO-receptor agonists, measurement of TPO levels might be important to differentiate the mechanism of thrombocytopenia.
我们检测了数名血小板减少症患者的血浆血小板生成素（TPO）水平。与之前的报道相似，再生障碍性贫血患者（n = 9）的TPO水平显著高于特发性血小板减少性紫癜患者（n = 10）：分别为16.19±9.07 fmol/ml和1.21±1.06 fmol/ml。在血小板恢复继发失败的患者（n = 7）以及造血干细胞移植后原发性失败的患者中，TPO水平非常高，这反映了由于移植物抗宿主病、药物治疗和感染导致的血小板生成受损。当使用TPO受体激动剂等新药时，检测TPO水平对于鉴别血小板减少症的机制可能很重要。
